Co-Diagnostics, a molecular diagnostics firm, announced its submission of a 510(k) premarket notification to the FDA for its Co-Dx PCR Flu A/B & RSV multiplex test on the Co-Dx PCR Pro® platform. This test, developed during the pandemic, is pending FDA clearance and aims to expand PCR diagnostic access globally. The company is preparing for a potential U.S. launch while pursuing international regulatory approvals. Their Chief Commercialization Officer also recently discussed medical device innovation and AI impacts at a Salt Lake City industry event.
Amazon's stock has risen over 15% following a record Q2 performance, with Morgan Stanley analyst Brian Nowak reiterating a 'Buy' rating and setting a 12-month price target of $335, implying a 28.6% potential gain. The firm also forecasts a long-term ...
Meta Platforms has seen its stock drop about 27% year-to-date, underperforming the broader market. This decline is largely due to one-time legal and severance costs that have compressed margins and caused earnings misses. However, these charges are e...
Skeleton Coast Uranium has finished digitising historical exploration data for three key uranium licences in Namibia's Erongo Region, enhancing its understanding of potential uranium deposits. This data-driven approach identifies high-priority target...
Almonty Industries is emerging as the leading Western producer of tungsten, benefiting from China's export ban and rising tungsten prices. Its Sangdong mine, known for high-grade ore and low costs, is expanding in phases fully financed to meet over 2...
Ripple's President Monica Long emphasized XRP's central role in creating an 'Internet of Value' during her keynote at MERGE São Paulo, highlighting Ripple's strong regulatory compliance with over 75 licenses worldwide. This approach aims to provide a...
